Patent · US Active

Expression and export of angiogenesis inhibitors as immunofusins

US8703908B2 · kind B2 · utility

1Cited by

3References

17Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Kin-Ming Lo · Lexington, US
Yue Li · Shanghai, CN
Stephen D. Gillies · Carlisle, US

Key dates

Filing date	Jun 26, 2012
Grant date	Apr 22, 2014
Priority date	—
Expiry date	Jun 26, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/81
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A fusion protein of the invention comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein comprises a collagen XVIII fragment, preferably endostatin. The immunoglobulin Fc region preferably comprises a hinge region, a CH2 region, and a CH3 region.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.